Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).
Pathology and disease mechanisms in different stages of multiple sclerosis.
Motivational interviewing may improve exercise experience for people with multiple sclerosis: A small randomized trial.
Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions.
Natalizumab in spinal multiple sclerosis in a daily clinical setting.
Regulated microRNAs in the CSF of patients with multiple sclerosis: A case-control study.
T-bet or not T-bet: Taking the last bow on the autoimmunity stage.
Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.
Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids.
The thalamus and multiple sclerosis: Modern views on pathologic, imaging, and clinical aspects.
Modifiable Comorbidities and Disability in Multiple Sclerosis.
Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS.
Transcriptomic meta-analysis of multiple sclerosis and its experimental models.
Small Molecules in Stem Cell Research.
The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.
Citrullination of Histone H3 Interferes with HP1-Mediated Transcriptional Repression.
Effects of multidisciplinary rehabilitation on chronic fatigue in multiple sclerosis: a randomized controlled trial.
Imatinib-induced amelioration of neurologic deficits in a rare case of simultaneous association of missed multiple sclerosis and chronic myeloblastic leukemia.
Review: the role of vitamin D in nervous system health and disease.
The Afferent Visual Pathway: Designing a Structural-Functional Paradigm of Multiple Sclerosis.
Effects of vitamin d3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells.
[Application of laser therapy in the physiotherapy of patients with multiple sclerosis].
Tysabri screening test may be unreliable
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.
Pages
« first
‹ previous
…
179
180
181
182
183
184
185
186
187
…
next ›
last »